14 results
8-K
EX-1.1
PRLD
Prelude Therapeutics Inc
19 May 23
Prelude Therapeutics Announces Launch of Proposed Public Offering
4:06pm
to the retention of such counsel or (ii) the named parties to any such proceeding (including any impleaded parties) include both the indemnifying
PRE 14A
PRLD
Prelude Therapeutics Inc
18 Apr 23
Preliminary proxy
4:00pm
granted to Dr. Huang in 2022.
(7)Amount represents retention bonus paid to Dr. Scherle in November 2022.
Non-Equity Incentive Plan Compensation
S-3
EX-4.5
ai6x4
12 Nov 21
Shelf registration
4:02pm
8-K
EX-99.2
rbbeq142i6er7
12 Nov 21
Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update
7:57am
8-K
0y6s 1rn9
12 Nov 21
Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update
7:57am
S-1
EX-10.1
d5iosdn lv
4 Sep 20
IPO registration
4:48pm
- Prev
- 1
- Next